STOCKS NEWS EUROPE-Wilmington up; in-line FY, RBS upgrade

Shares in Wilmington Group Plc (WIL.L) rise 6 percent to 129 pence after the publishing and professional training company posts full-year profits in line with market estimates and RBS upgrades to "buy".

"Directionally, the results were as expected," says analyst Dominic Buch of Numis Securities.

"While our forecasts assume continued near-term pressure in the legal and financial industries, we believe that Wilmington is well-managed (and) structurally sound with a strong balance sheet," adds Buch, who has a "buy" rating on the stock.

Separately, RBS upgrades Wilmington to "buy" from "add" and raises its price target on the stock to 150 pence from 114 on valuation grounds, citing resilient final results despite tough conditions.

For more, click on [ID:nBNG36338]

Reuters messaging rm://tresa.sherin.reuters.com@reuters.net

07:55GMT 17Sep2009-ReNeuron falls on later-than-expected trial date

-------------------------------------------------------------------

Shares in stem cell specialist ReNeuron (RQE.L) tumble 16 percent after the company says in an update ahead of its AGM that it expects to start its first human trial in late 2009 or early 2010, later than investors had anticipated.

"There's a delay compared to what the market was expecting," says analyst Vadim Alexandre at house brokerage Daniel Stewart, adding that it is good news, however, that the company is now able to announce a specific timeline.

To see ReNeuron's statement please click on [ID:nRnsQ1998Z]

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net

07:43GMT 17Sep2009-Antofagasta up on Cazenove upgrade

-----------------------------------------------------